Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

Nektar Therapeutics (NASDAQ:NKTR) announced Tuesday that its lead asset, rezpegaldesleukin, reached the main goal in a ...

Nektar Therapeutics (NASDAQ:NKTR) saw its stock soar 140% following promising Phase 2b trial results for its experimental treatment rezpegaldesleukin in moderate-to-severe atopic dermatitis. The ...

Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...

Achieved statistical significance on primary endpoint at week 16 for mean percent change in EASI score from baseline for all rezpegaldesleukin arms versus placebo Achieved statistical significance for ...

Investing.com -- Nektar Therapeutics (NASDAQ: NKTR) stock surged 140% after the company announced its experimental drug rezpegaldesleukin met primary and key secondary endpoints in a Phase 2b study ...

Easi-Set Worldwide, a subsidiary of Smith-Midland Corporation (NASDAQ:SMID), is excited to announce a new licensing agreement with Infrastructure Precast Inc. (ICast) of Kentucky. Under this ...

EASI can immediately help the DEA maximize its ability to discriminate between different strains of emerging synthetic drugs." Jackson said he believes there is no time to waste in improving ...